DK2240570T3 - Bakteriel ghostproduktionsproces (BG) under anvendelse af betapropiolacton (BLP) til slutinaktivering - Google Patents
Bakteriel ghostproduktionsproces (BG) under anvendelse af betapropiolacton (BLP) til slutinaktivering Download PDFInfo
- Publication number
- DK2240570T3 DK2240570T3 DK09702047.3T DK09702047T DK2240570T3 DK 2240570 T3 DK2240570 T3 DK 2240570T3 DK 09702047 T DK09702047 T DK 09702047T DK 2240570 T3 DK2240570 T3 DK 2240570T3
- Authority
- DK
- Denmark
- Prior art keywords
- bacterial
- gene
- ghost
- enzyme
- bacterial cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0283—Shigella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (17)
1. Fremgangsmåde til fremstilling af en bakteriel g hostf re msti 11 i ng omfattende at behandle nævnte bakterielle ghost med betapropiolacton.
2. Fremgangsmåde ifølge krav 1 omfattende trinnene: (a) produktion af en bakteriel ghosttilberedning, og (b) efterfølgende behandling af den bakterielle ghosttilberedning med betapropiolacton ved betingelser, hvor antallet af eventuelle tilbageværende levende bakterieceller i nævnte ghosttilberedning er reduceret.
3. Fremgangsmåde ifølge krav 1 eller 2, hvor antallet af eventuelle tilbageværende levende bakterielle celler i nævnte ghosttilberedning er reduceret med mindst 103 - 104.
4. Fremgangsmåde ifølge krav 1 - 3, hvor de bakterielle ghost er behandlet med 0,01 -1 volumen% betapropiolacton som slutkoncentration.
5. Fremgangsmåde ifølge krav 1 - 4, hvor betapropiolactontilsætning udføres i to konsekutive trin.
6. Fremgangsmåde ifølge krav 1 - 5, hvor betapropiolactontilsætningen udføres ved 26 - 50°C, og hvor den bakterielle ghost inaktiveres i 10 - 60 minutter.
7. Fremgangsmåde ifølge et vilkårligt af kravene 1 - 6, hvor den bakterielle ghostfremstilling er opnået ved: (a) tilvejebringelse af bakterielle celler omfattende et gen, som koder for et lytisk protein i stand til at danne en tunnelstruktur i det bakterielle cellekappes kompleks, (b) udsættelse af den bakterielle celle for tilstande, hvor det lytiske gen udtrykkes, og de cytoplasmiske komponenter af de bakterielle celler frisættes, og (c) opnåelse af de resulterende bakterielle ghostbakterier.
8. Fremgangsmåde ifølge et vilkårligt af kravene 1 - 6. hvor den bakterielle ghosttilberedning er opnået ved: (a) tilvejebringelse af bakterielle celler omfattende et gen, som koder for et lytisk protein i stand til at danne en tunnelstruktur i det bakterielle cellekap-pekompleks, (b) dyrkning af de bakterielle celler ved tilstande, hvor det lytiske gen ikke udtrykkes, (c) udsættelse af den bakterielle celle for betingelser, hvor det lytiske gen udtrykkes, og de cytoplasmiske komponenter af de bakterielle celler frisættes, og (d) opnåelse af den resulterende bakterielle ghost.
9. Fremgangsmåde ifølge krav 7 eller 8, hvor de bakterielle celler yderligere koder for et enzym i stand til at hydrolysere cytoplasmiske komponenter i den bakterielle celle omfattende følgende trin: udsættelse af den bakterielle celle for betingelser, hvor enzymgenet udtrykkes, og de cytoplasmiske komponenter af de bakterielle celler nedbrydes.
10. Fremgangsmåde ifølge krav 7 eller 8, hvor de bakterielle celler yderligere koder for et enzym i stand til at hydrolysere cytoplasmiske komponenter i bakterievæggen, omfattende følgende trin: (a) eventuelt dyrkning af de bakterielle celler under tilstande, hvor enzymgenet ikke udtrykkes, (b) udsættelse af den bakterielle celle for betingelser, hvor enzymgenet udtrykkes, og de cytoplasmiske komponenter i de bakterielle celler nedbrydes.
11. Fremgangsmåde ifølge krav 9 eller 10, hvor genet, som koder for det hy-drolytiske enzym, er et nucleasegen.
12. Fremgangsmåde ifølge et vilkårligt af kravene 7-11, hvor det lytiske gen og enzymgenet er i operativ forbindelse med en regulatorisk dygtig ekspressionskontrolsekvens, hvor det lytiske gen og enzymgenet er på én eller flere vektorer.
13. Fremgangsmåde ifølge krav 12, hvor ekspressionen af det lytiske gen og ekspressionen af enzymet induceres til forskellige tider.
14. Farmaceutisk sammensætning omfattende et betapropiolactonbehandlet bakteriel ghosttilberedning og en farmaceutisk acceptabel bærer, fortyndingsmiddel og/eller adjuvans.
15. Sammensætning ifølge krav 14, som er en vaccine eller er en adjuvans.
16. Sammensætning ifølge krav 15 til anvendelse i human medicin eller til anvendelse i veterinær medicin.
17. Anvendelse af betapropiolacton ved fremstilling af en bakteriel ghosttilberedning.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2197708P | 2008-01-18 | 2008-01-18 | |
| PCT/EP2009/000272 WO2009090093A1 (en) | 2008-01-18 | 2009-01-16 | Bacterial ghost (bg) production process using betapropiolactone (blp) for final inactivation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2240570T3 true DK2240570T3 (da) | 2014-03-10 |
Family
ID=40532591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09702047.3T DK2240570T3 (da) | 2008-01-18 | 2009-01-16 | Bakteriel ghostproduktionsproces (BG) under anvendelse af betapropiolacton (BLP) til slutinaktivering |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7968323B2 (da) |
| EP (1) | EP2240570B1 (da) |
| CN (1) | CN102224237B (da) |
| AU (1) | AU2009204952B2 (da) |
| CA (1) | CA2710814C (da) |
| DK (1) | DK2240570T3 (da) |
| ES (1) | ES2452471T3 (da) |
| NZ (1) | NZ586669A (da) |
| PL (1) | PL2240570T3 (da) |
| PT (1) | PT2240570E (da) |
| RU (1) | RU2520082C2 (da) |
| SI (1) | SI2240570T1 (da) |
| WO (1) | WO2009090093A1 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101934072B (zh) * | 2010-03-24 | 2012-05-23 | 天津农学院 | 一种制备App菌影的方法及App菌影装载巴氏杆菌抗原制备亚单位疫苗的方法 |
| CN101991863B (zh) * | 2010-04-28 | 2012-11-07 | 中国人民解放军军事医学科学院野战输血研究所 | 一种双重靶向dna疫苗及其构建方法 |
| PL2591798T3 (pl) * | 2011-11-09 | 2015-04-30 | Werner Lubitz | Szczepionka do zastosowania w immunoterapii nowotworów |
| CN103436550B (zh) * | 2013-07-26 | 2015-04-15 | 黑龙江八一农垦大学 | 一种菌影载体的构建方法 |
| US9796960B2 (en) * | 2014-01-13 | 2017-10-24 | Mingjie Zhang | Method for preparing and using cell ghost with active factors as synergist of lymphocyte in vitro culture |
| US10526574B2 (en) | 2014-02-21 | 2020-01-07 | Bird-C Gmbh & Co. Kg | Fed-batch process for the production of bacterial ghosts |
| EP3195878A1 (en) | 2016-01-22 | 2017-07-26 | Werner Lubitz | Bacterial ghosts for the treatment of cancer |
| KR101825439B1 (ko) | 2016-04-15 | 2018-02-05 | 배재대학교 산학협력단 | 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법 |
| EP3700552A1 (en) | 2017-10-25 | 2020-09-02 | Allero Therapeutics BV | Treatment of immune diseases by administration of antigen-specific formulations |
| KR102178334B1 (ko) | 2019-01-29 | 2020-11-12 | 배재대학교 산학협력단 | 황산을 이용하는 박테리아 고스트 제조방법, 상기 방법으로 제조된 박테리아 고스트 및 이의 용도 |
| CN110812473A (zh) * | 2019-12-10 | 2020-02-21 | 广东君睿生物技术研究有限公司 | 一种副猪嗜血杆菌病、猪链球菌病和猪多杀性巴氏杆菌病三联灭活疫苗及其制备方法 |
| CN110951666A (zh) * | 2019-12-27 | 2020-04-03 | 江苏农牧科技职业学院 | 一种双蛋白表达的大肠杆菌菌蜕及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2989435A (en) * | 1957-01-03 | 1961-06-20 | Philips Corp | Method of chemical sterilization of aqueous liquids containing bacteria or spores ofbacteria |
| DE3715840A1 (de) | 1987-05-12 | 1988-12-01 | Boehringer Mannheim Gmbh | Fuer ein lytisch wirksames, chimaeres protein kodierende rekombinante dna und ihre verwendung |
| DE4005874A1 (de) | 1990-02-24 | 1991-11-07 | Boehringer Mannheim Gmbh | Traegergebundene rekombinante proteine, verfahren zur herstellung und verwendung als immunogene und vakzine |
| JPH05503432A (ja) | 1990-03-07 | 1993-06-10 | エンゲルハード・コーポレーシヨン | 動物飼料添加剤および動物飼料中に存在するマイコトキシンの不活性化方法 |
| EP0674905B1 (en) * | 1990-06-07 | 2002-12-11 | Bayer Corporation | Bacterin for the treatment of liver necrosis caused by F. necrophorum |
| RU2059417C1 (ru) * | 1992-10-01 | 1996-05-10 | Данилевич Василий Николаевич | Способ стерилизации питательных сред |
| DE10003241A1 (de) | 2000-01-26 | 2001-08-02 | Werner Lubitz | Verschließen von Bakterienghosts |
| DE60235809D1 (de) * | 2001-07-11 | 2010-05-12 | Werner Lubitz | Nukleinsäurefreie ghost zusammensetzungen |
| WO2005001059A2 (en) * | 2003-06-23 | 2005-01-06 | Novasterilis Inc. | Inactivating organisms using carbon dioxide at or near its supercritical pressure and temperature conditions |
| DE10335796A1 (de) | 2003-08-05 | 2005-03-03 | Lubitz, Werner, Prof. Dr. | Verschliessen von Bakterienghosts durch bioaffine Wechselwirkungen |
-
2009
- 2009-01-16 EP EP09702047.3A patent/EP2240570B1/en not_active Not-in-force
- 2009-01-16 CA CA2710814A patent/CA2710814C/en active Active
- 2009-01-16 DK DK09702047.3T patent/DK2240570T3/da active
- 2009-01-16 SI SI200930872T patent/SI2240570T1/sl unknown
- 2009-01-16 ES ES09702047.3T patent/ES2452471T3/es active Active
- 2009-01-16 AU AU2009204952A patent/AU2009204952B2/en not_active Ceased
- 2009-01-16 PL PL09702047T patent/PL2240570T3/pl unknown
- 2009-01-16 CN CN200980102422.7A patent/CN102224237B/zh not_active Expired - Fee Related
- 2009-01-16 WO PCT/EP2009/000272 patent/WO2009090093A1/en active Application Filing
- 2009-01-16 RU RU2010134400/10A patent/RU2520082C2/ru not_active IP Right Cessation
- 2009-01-16 NZ NZ586669A patent/NZ586669A/en not_active IP Right Cessation
- 2009-01-16 PT PT97020473T patent/PT2240570E/pt unknown
- 2009-01-21 US US12/356,703 patent/US7968323B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| NZ586669A (en) | 2012-06-29 |
| EP2240570A1 (en) | 2010-10-20 |
| EP2240570B1 (en) | 2013-12-11 |
| CN102224237B (zh) | 2014-03-12 |
| CA2710814A1 (en) | 2009-07-23 |
| SI2240570T1 (sl) | 2014-04-30 |
| US20100092516A1 (en) | 2010-04-15 |
| ES2452471T3 (es) | 2014-04-01 |
| PL2240570T3 (pl) | 2014-05-30 |
| CA2710814C (en) | 2014-10-14 |
| RU2010134400A (ru) | 2012-02-27 |
| AU2009204952B2 (en) | 2013-02-07 |
| PT2240570E (pt) | 2014-02-17 |
| RU2520082C2 (ru) | 2014-06-20 |
| WO2009090093A1 (en) | 2009-07-23 |
| US7968323B2 (en) | 2011-06-28 |
| CN102224237A (zh) | 2011-10-19 |
| AU2009204952A1 (en) | 2009-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2240570T3 (da) | Bakteriel ghostproduktionsproces (BG) under anvendelse af betapropiolacton (BLP) til slutinaktivering | |
| EP0555366B1 (en) | Bacterial attenuation method and vaccine | |
| CN104159601B (zh) | 弯曲杆菌属免疫原性组合物及其用途 | |
| US20110014157A1 (en) | Method for producing a mixture of bacteriophages and the use thereof in the therapy of antibiotic-resistant staphylococci | |
| EP3160224B1 (en) | In ovo delivery of probiotic cultures | |
| CN113491767A (zh) | 鸭圆环病毒病、新型鸭呼肠弧病毒病、鸭病毒性肝炎三联灭活疫苗及其制备方法 | |
| CN112695005A (zh) | APEC双sRNA基因缺失菌株及由其制备的弱毒疫苗 | |
| CN110016457B (zh) | 一株重组细粒棘球蚴Eg95基因的粗糙型布鲁氏菌及其疫苗生产方法 | |
| US4472378A (en) | Live vaccine for the prevention of salmonellosis in water fowl, a process for making and applying the same | |
| JP5483731B2 (ja) | 保存可能な生虫卵懸濁液の製造 | |
| AU2002328340B2 (en) | Nucleic acid free ghost preparations | |
| JP5121230B2 (ja) | Ｑ熱のワクチン製剤および該ワクチン製剤の製造方法 | |
| AU2002328340A1 (en) | Nucleic acid free ghost preparations | |
| US20230173053A1 (en) | Lyophilized Live Bordetella Vaccines | |
| RU2741643C1 (ru) | Ассоциированная вакцина против миксоматоза, пастереллёза и вирусной геморрагической болезни кроликов 1 и 2 типов | |
| CN118667702A (zh) | 一种猪肺炎支原体高密度发酵培养基、发酵培养工艺及其应用 | |
| CN114668838A (zh) | 防治鸭圆环病毒病、新型鸭呼肠孤病毒病、鸭病毒性肝炎和鸭腺病毒3型的四联灭活疫苗 | |
| CN118345017A (zh) | 禽多杀性巴氏杆菌透明质酸合成酶敲除的突变菌株及其应用 | |
| KR20230164829A (ko) | 박테리오파지를 포함하는 살모넬라 엔테리티디스 증식 억제용 조성물 | |
| CN116284261A (zh) | 一种非洲猪瘟病毒结构蛋白组合物及其制备的疫苗 | |
| Rousseau et al. | Improvements in the fermenter growth of Brucella abortus strain 19 | |
| CN118726271A (zh) | 一种悬浮培养的猫杯状病毒减毒活疫苗及其应用 | |
| RU2388487C1 (ru) | Способ изготовления вакцины против псевдомоноза нутрий | |
| NO791690L (no) | Fremgangsmaate for immunisering av fisk | |
| TW200525031A (en) | Method for producing virus-like particles of Infectious Bursal Disease viruses by E. coli and its application in subunit vaccine |